104795-66-6
Chemical Structure
CI-959 free acid
- CAS No.: 104795-66-6
- Formula:C14H15N5O3S
- Molecular Weight:333.37
IUPAC Name: 3-isopropoxy-5-methoxy-N-(2H-tetrazol-5-yl)benzo[b]thiophene-2-carboxamide
InChIKey: TVVXHFWWAYXBNC-UHFFFAOYSA-N
SMILES: O=C(C1=C(OC(C)C)C2=CC(OC)=CC=C2S1)NC3=NNN=N3
Biological Activity: CI-959 free acid is an orally active cell activation inhibitor. CI-959 free acid selectively suppresses inflammatory cell activation post-receptor signaling via inhibiting calcium influx and weak calmodulin antagonism, without targeting PLC, PKC or NADPH oxidase. CI-959 free acid blocks lung allergic mediator release, anti-IgE bronchial contraction, neutrophil function, T-cell proliferation and DC marker expression while sparing monocytes. CI-959 free acid provides gastric cytoprotection by inhibiting leukocyte adhesion and suppresses tumor motility through F-actin reduction. CI-959 free acid can be used for research on allergies, inflammation, autoimmune diseases, gastric injury, and tumor metastasis [1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CI-959 free acid | CI-959 free acid is an orally active cell activation inhibitor. CI-959 free acid selectively suppresses inflammatory cell activation post-receptor signaling via inhibiting calcium influx and weak calmodulin antagonism, without targeting PLC, PKC or NADPH oxidase. CI-959 free acid blocks lung allergic mediator release, anti-IgE bronchial contraction, neutrophil function, T-cell proliferation and DC marker expression while sparing monocytes. CI-959 free acid provides gastric cytoprotection by inhibiting leukocyte adhesion and suppresses tumor motility through F-actin reduction. CI-959 free acid can be used for research on allergies, inflammation, autoimmune diseases, gastric injury, and tumor metastasis . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Walsh KM, et al. Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Toxicol Pathol. 1998 Nov-Dec;26(6):717-23. [Content Brief]
- [2]. Bleavins MR, et al. Immunotoxicologic studies with CI-959, a novel benzothiophene cell activation inhibitor. Toxicology. 1995 Apr 12;98(1-3):111-23. [Content Brief]
- [3]. Wright CD, et al. Selective regulation of human neutrophil functions by the cell activation inhibitor CI-959. J Leukoc Biol. 1994 Apr;55(4):443-51. [Content Brief]
- [4]. Low J, et al. Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33. [Content Brief]
- [5]. Adolphson RL, et al. CI-959, a new, potential antiallergic drug, inhibits mediator release from lung and contractions of human airways in vitro. Int Arch Allergy Appl Immunol. 1990;93(2-3):267-71. [Content Brief]
- [6]. Dong MK, et al. Inhibition of interleukin-2 production and lymphocyte responsiveness by the cell activation inhibitor, CI-959. Agents Actions. 1991 Sep;34(1-2):53-5. [Content Brief]
- [7]. von Tscharner Biino N, et al. Suppression of polarity, locomotion and F-actin levels of Walker carcinosarcoma cells by the inhibitor CI-959. Life Sci. 1997;61(2):137-45. [Content Brief]
- [8]. Low JE, et al. Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: morphologic features and pharmacokinetic and pharmacodynamic mechanisms. J Cardiovasc Pharmacol. 1995 Jun;25(6):930-9. [Content Brief]
